

Therapeutics Advisory Group Update - Issue 25 – October 2023

All recommendations discussed at the **September** TAG and D+TC meetings and ratified by the Planned Care and Medicines Management Working Group on behalf of the ICB – **October 2023**. Please share within your organisation as appropriate

Commissioning Summary

Formulary application - Avatrombopag for treating primary chronic immune thrombocytopenia as per TA853	<ul style="list-style-type: none"> Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care
Formulary application - Relugolix–estradiol–norethisterone acetate (Ryeqo®) for moderate to severe fibroid symptoms in adult women of reproductive age as per TA832	<ul style="list-style-type: none"> ADVICE - SPECIALIST INITIATION: First three months to be supplied by specialist before transfer to primary care
Commissioning Review – Nasal Sprays: <ul style="list-style-type: none"> Azelastine and Fluticasone (Dymista®) Olopatadine and Mometasone furoate (Ryaltris®) 	<ul style="list-style-type: none"> Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care pending formulary application. Classification covers new patients. Existing patients may continue without change until they and their NHS clinician consider it appropriate to stop.
Commissioning Review - Lift Juice Glucose Shots	<ul style="list-style-type: none"> BLACK – not commissioned. No prescribing primary or secondary care
Commissioning Review - Semaglutide for managing overweight and obesity in adults as per TA875	<ul style="list-style-type: none"> Updated to Red Specialist Use Only - only to be supplied via Tier 3 service
Commissioning Review – Inclisiran – Advice bulletin developed to remind prescribers of current position	<ul style="list-style-type: none"> ADVICE - Specialist advice required from clinician with relevant expertise prior to initiation Restricted for use only in those patients who meet the criteria listed in the NICE guidance – TA733
Commissioning Review – Covid-19 treatment classifications updated following change to ICB-commissioning.	<ul style="list-style-type: none"> See Netformulary for latest recommendations. Please note - for patients to enter the covid-19 pathway, they must phone 111 who will triage them to the Community Covid Medicines Service (CCMS) within our out of hours provider IC24. If appropriate, Electronic Prescription will be sent to one of the commissioned pharmacies to supply
Netformulary Updates <ul style="list-style-type: none"> Hydramed Night sensitive eye ointment - Netformulary entry updated to 'This is only available over-the-counter as not in the Drug Tariff / not possible to prescribe on an FP10' Knox mouthwash (Triamcinolone and Erythromycin) - Red/Hospital classification Estradiol 1.53mg/spray (Lenzetto®) - Amended to Green - Drugs that can be initiated by Prescriber in Primary Care in line with other oestrogens 	
<p>We have several sections live on Netformulary. If you have any formulary queries, please remember to check there first before emailing the generic inbox</p>	

Shared Care Updates

Shared Care Agreement in development <ul style="list-style-type: none"> Lithium 	<ul style="list-style-type: none"> Noted as part of wider piece of work Will return to TAG in due course
---	--

NICE Guidance – acknowledged by the TAG

NG83 – Jan 2018, updated July 2023 - Oesophago-gastric cancer: assessment and management in adults
NG122 – March 2019, updated July 2023 - Lung cancer: diagnosis and management
CG189 – Nov 2014, updated July 2023 - Obesity: identification, assessment and management
NG158 – March 2020, updated August 2023 - Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
NG12 – June 2015, updated August 2023 - Suspected cancer: recognition and referral
NG233 – August 2023 - Otitis media with effusion in under 12s

NICE Technology Appraisals – ICB Commissioning Responsibility

None this month	
-----------------	--

NICE Technology Appraisals – NHS England Commissioning Responsibility

TA908 – July 2023 - Olaparib (Lynparza®) for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy	RED/HOSPITAL - Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care
TA911 – July 2023 - Selpercatinib (Retsevmo®) for untreated RET fusion-positive advanced non-small-cell lung cancer	
TA912 – August 2023 - Cipaglucosidase alfa (Pombiliti®) with miglustat for treating late-onset Pompe disease	
TA909 – July 2023 - Lorlatinib (Lorviqua®) for untreated ALK-positive advanced non-small-cell lung cancer	BLACK - Not commissioned. No NHS prescribing in primary or secondary care. Not recommended by NICE

NICE Technology Appraisals – Terminated Appraisals

TA910 – July 2023 - Semaglutide (Wegovy®) for managing overweight and obesity in young people aged 12 to 17 years	BLACK - Not commissioned. No NHS prescribing in primary or secondary care. Not recommended by NICE
---	---

NICE NHS England Highly Specialised Technologies

HST27 – July 2023 - Afamelanotide (Scenesse®) for treating erythropoietic protoporphyria	BLACK - Not commissioned. No NHS prescribing in primary or secondary care. Not recommended by NICE
--	---

Useful Information

Tirzepatide commissioning	Holding statement published on KA
Daridorexant commissioning	Holding statement published on KA
Next meeting	Wednesday 1st November 2023
Deadline for agenda submissions	Tuesday 24th October 2023